{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015883","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.896292+00:00","generated_at":"2026-05-29T20:44:12.395994+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"uniQure doses first patient in Phase I/IIa trial of AMT-260 for refractory temporal lobe epilepsy","bullets":["First patient dosed in GenTLE Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy (MTLE).","AMT-260 uses AAV9 vector to deliver miRNAs that reduce GluK2 protein subunit expression, targeting seizure triggers.","Trial includes two dose cohorts of six patients each across 10 U.S. sites; two more sites expected by end of 2024.","CMO Walid Abi-Saab notes 1/3 of focal seizure patients lack effective treatment, highlighting potential for AMT-260.","Preclinical studies showed dose-dependent seizure reduction; program updates expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015883","json":"https://secwatch.observer/filing/0001558370-24-015883.json","markdown":"https://secwatch.observer/filing/0001558370-24-015883.md","text":"https://secwatch.observer/filing/0001558370-24-015883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/0001558370-24-015883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/qure-20241121x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:44:12.395994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}